TVS Motor Company launches its revolutionary premium electric crossover, TVS X; sets new global benchmarks in the EV industry
24.8.2023 13:38:00 EEST | Business Wire | Press release
In line with its commitment towards offering sustainable mobility solutions globally, TVS Motor Company, a reputed manufacturer of two and three-wheelers, today launched the keenly anticipated, TVS X its flagship crossover EV with a host of industry first attributes. This revolutionary machine sets a new benchmark in the global electric mobility industry with its stunning design, unmatched performance, and cutting-edge tech features, carving out a new category in the electric mobility segment. As a frontrunner in sustainable mobility solutions, TVS Motor Company aims to transform the EV segment and reaffirm its commitment to a more sustainable and cleaner future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230824401679/en/
Mr. Sudarshan Venu, MD, TVS Motor Company at the launch of TVS X in Dubai (Photo: Business Wire)
With a rapid uptick in the adoption of EVs globally, the TVS X will play a pivotal role in creating a niche in the EV industry. Backed by rider-first engineering, to deliver rider-machine unity, this lean-mean-clean machine designed to create desire, has been developed from the ground up at TVS Motor’s R&D facility. Designed, developed, and made-in-India, TVS X comes with a powerful electric motor and advanced battery technology. This machine promises not only thrilling acceleration but also an impressive range, ensuring convenience and comfort, thus making it an ideal zero-emission and sophisticated electric mobility solution. This flagship EV from the house of TVS Motor introduces not only stellar performance, but also an array of safety features, with a number of class leading offerings in line with its vision of creating a clean, intuitive and tech-first product. It is designed for young Indians who are the global trendsetters.
Speaking at the launch, Mr. Sudarshan Venu, Managing Director, TVS Motor Company said, “Our dedication to harness technology and innovation towards a greener and more sustainable future has brought to us this incredibly desirable machine. This launch marks a defining moment in TVS Motors’ journey of showcasing a made-in-India EV, the TVS X. It has been designed for the global citizens, who are trendsetters and visionaries with a passion for technology. It is set to inspire a shift towards premium yet sustainable and technologically advanced mobility solutions. It leads the way to become a global benchmark for a machine that is born electric. The TVS X embodies innovation with a disruptive mindset. It has sustainability at its core and embodies the next era of clean mobility. With its remarkable performance, premium aesthetics, and integrated, intuitive, and personalised experiences, we believe it will redefine mobility worldwide.”
Booking for TVS X are open now on our website https://www.tvsmotor.com/electric-vehicle/tvs-x. Deliveries across 15 cities will start from Nov 2023 in a phase-wise manner.
TVS X will be available at a Thrill-electric introductory price of INR. 2,49,990/- (Ex-showroom Bengaluru) with portable 950W chargers at INR. 16,275 (including GST) and a 3kW Smart X Home rapid charger is also available as an option. FAME incentive is not applicable for TVS X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230824401679/en/
Contact information
For more information, please contact:
KS Harini – ks.harini@tvsmotor.com
Nikita Verma – nikita.verma@tvsmotor.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom